Latest news with #BaxterInternational
Reuters
4 days ago
- Health
- Reuters
US FDA says country's IV, injectable saline shortage is resolved
Aug 8 (Reuters) - A shortage of intravenous and injectable saline solutions in the United States has now been resolved, U.S. Food and Drug Administration commissioner Martin Makary said on Friday. The shortage partly stems from Baxter International's (BAX.N), opens new tab North Carolina plant getting damaged in Hurricane Helene last year. At that time, the Marion, North Carolina site was producing 60% of the nation's supply of IV fluids and peritoneal dialysis solutions, amounting to 1.5 million bags daily, according to the American Hospital Association. A shortage of IV fluids, which provide nutrients to the body or replenish fluids lost due to injury or illness, had forced hospitals to curtail elective procedures.
Yahoo
7 days ago
- Business
- Yahoo
Baxter International Inc. (BAX): A Bull Case Theory
We came across a bullish thesis on Baxter International Inc. on DeepValue Capital's Substack. In this article, we will summarize the bulls' thesis on BAX. Baxter International Inc.'s share was trading at $22.44 as of August 4th. BAX's trailing and forward P/E were 84.46 and 8.71, respectively according to Yahoo Finance. Baxter International (BAX), a nearly century-old leader in lifesaving medical technologies, has seen its shares collapse over 75% from peak levels, now trading at less than 8x normalized free cash flow versus a historical median of 24x. The company operates across critical healthcare segments, including medical products, infusion systems, advanced surgical tools, pharmaceuticals, and connected-care platforms, serving hospitals, surgical centers, and home-care patients globally. Recent divestitures, including the Vantive kidney-care spin-off and biopharma solutions unit, have streamlined operations and generated over $3 billion in proceeds, positioning Baxter for margin expansion and strategic reinvestment. New CEO Andrew Hider, effective September 2025, brings a strong track record of operational improvement and value creation, with plans to cut stranded costs, modernize supply chains, and accelerate R&D into next-generation infusion systems and AI-powered surgical solutions. These efforts aim to achieve a 16.5% adjusted operating margin in 2025 and return Baxter to growth mode. Industry tailwinds add support, with large addressable markets in IV solutions, infusion pumps, smart beds, and generic injectables all projected to grow at mid-to-high single-digit CAGRs. NeAar-term catalysts include hospital volume recovery post-inventory destocking, a revamped Novum IQ infusion pump, and continued simplification. Risks remain—product safety issues, litigation, regulatory hurdles, and macro softness—but Baxter's financial flexibility and leadership change provide a credible path forward. With normalized growth, margin recovery, and a rerating to historical valuation multiples, shares could exceed $70 by 2028, representing a potential 250% return and an attractive turnaround opportunity in the large-cap healthcare sector. Previously, we covered a on Intuitive Surgical, Inc. (ISRG) by The Antifragile Investor in January 2025, which highlighted the company's dominance in robotic surgery through its da Vinci system, strong IP moat, and recurring revenue model. The company's stock price has depreciated by approximately 10.3% since our coverage. This is because growth expectations were moderated, but the thesis still stands due to its entrenched leadership. DeepValue Capital shares a similar view on healthcare innovation but emphasizes a valuation-driven turnaround in Baxter with restructuring and new leadership as key catalysts. Baxter International Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held BAX at the end of the first quarter which was 36 in the previous quarter. While we acknowledge the potential of BAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-08-2025
- Business
- Yahoo
Are Wall Street Analysts Bullish on Baxter International Stock?
Valued at a market cap of $11.3 billion, Baxter International Inc. (BAX) is a global healthcare and medtech company headquartered in Deerfield, Illinois. It specializes in medical products and pharmaceuticals focused on intravenous (IV) therapy, surgical care, anesthesia, drug compounding, and connected healthcare systems. Shares of BAX have lagged behind the broader market over the past 52 weeks. BAX has fallen 39% over this time frame, while the broader S&P 500 Index ($SPX) has gained 14.5%. Moreover, Baxter International stock has dipped 24.7% on a YTD basis, trailing SPX's 6.1% upstick. More News from Barchart Find Winning Momentum Trades With This Moving Average Stock Screener Tariffs, Earnings and Other Can't Miss Items this Week This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Looking closer, the medical products maker has also struggled to keep up with the Health Care Select Sector SPDR Fund's (XLV) 13.3% drop over the past 52 weeks and 4.7% plunge in 2025. On Jul. 31, Baxter posted its second-quarter earnings, and its shares dipped 22.4% as the company lowered its full-year guidance, projecting EPS of $2.42–$2.52, citing ongoing operational headwinds and cautious hospital spending. It reported revenue of $2.81 billion, up 4% year-over-year and in line with guidance, while adjusted EPS rose 28% to $0.59. For the current fiscal year, ending in December 2025, analysts expect BAX's EPS to grow 31.8% year-over-year to $2.49. The company's earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters, while missing on one occasion. Among the 15 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on four 'Strong Buy' ratings, ten 'Holds,' and one 'Moderate Sell.' This configuration is less bullish than a month ago, with five 'Strong Buy' ratings on the stock. On August 1, Wells Fargo & Company (WFC) analyst Larry Biegelsen maintained an "Equal-Weight" rating on Baxter International but sharply cut the price target from $33 to $24, a 27.3% reduction, reflecting a more cautious outlook on the stock. BAX's mean price target of $36.21 implies a 64.9% from the current market prices. The Street-high price target of $42 implies a robust potential upside of 91.3% from the current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
03-08-2025
- Business
- Yahoo
Baxter International (BAX) Falls to New Low on Disappointing Growth Forecast
We recently published . Baxter International Inc. (NYSE:BAX) is one of the worst-performing stocks on Thursday. Baxter International dropped its share prices to a new 52-week low on Thursday, as investors soured on its lower earnings growth forecast. At intra-day trading, shares of Baxter International Inc. (NYSE:BAX) dropped to their lowest price of $21.47 before ending the day down by 22.42 percent at $21.76 apiece. In a call with analysts, Baxter International Inc. (NYSE:BAX) said it lowered its adjusted EPS to between $2.42 and $2.52 from the $2.47 to $2.55. Analysts expected $2.52 per share. 'While we never want to lower expectations, our overall objective is reducing the outlook to capture more of the potential downside risks,' Baxter International Inc. (NYSE:BAX) CFO Joel Grade was quoted as saying, underscoring the demand weakness for IV fluids. Pixabay / Public Domain In the second quarter of the year, Baxter International Inc. (NYSE:BAX) swung to a net income attributable to shareholders of $91 million from a $314 million net loss in the same period last year. Net sales inched up by 4 percent to $2.8 billion from $2.69 billion. While we acknowledge the potential of BAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31-07-2025
- Business
- Yahoo
Why Baxter (BAX) Stock Is Falling Today
What Happened? Shares of healthcare company Baxter International (NYSE:BAX) fell 20% in the afternoon session after the company reported disappointing second-quarter results and cut its full-year profit forecast, citing the lingering impact of a hurricane. The healthcare company pointed to the lingering effects of Hurricane Helene, which damaged a key manufacturing facility and disrupted the supply of its IV solutions. Baxter's adjusted earnings per share of 59 cents missed analysts' estimates, while revenue of $2.81 billion also came in slightly below expectations. In response to these challenges and what management called demand softness, the company lowered its full-year profit guidance. The weak results and revised outlook prompted a negative reaction from investors. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Baxter? Access our full analysis report here, it's free. What Is The Market Telling Us Baxter's shares are not very volatile and have only had 7 moves greater than 5% over the last year. Moves this big are rare for Baxter and indicate this news significantly impacted the market's perception of the business. Baxter is down 22.3% since the beginning of the year, and at $22.74 per share, it is trading 43.5% below its 52-week high of $40.26 from September 2024. Investors who bought $1,000 worth of Baxter's shares 5 years ago would now be looking at an investment worth $263.20. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
